Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 16/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15701043 | 1.00 | FFAR2 (0.61) | FFAR2MEN1KMT2AHDAC3HDAC1 | |
| SCHEMBL19446696 | 1.00 | FFAR2 (0.61) | FFAR2MEN1KMT2AHDAC3HDAC1 | |
| SCHEMBL15701054 | 0.89 | NPC1 (0.48) | FFAR2MEN1KMT2AHDAC3HDAC1 | |
| SCHEMBL15701037 | 0.89 | NPC1 (0.48) | FFAR2MEN1KMT2AHDAC3HDAC1 | |
| SCHEMBL15701233 | 0.89 | NPC1 (0.48) | FFAR2MEN1KMT2AHDAC3HDAC1 | |
| SCHEMBL17148404 | 0.83 | RAB9A (0.42) | FFAR2MEN1KMT2ALMNA | |
| SCHEMBL15701131 | 0.82 | ALDH1A1 (0.43) | FFAR2MEN1KMT2ALMNA | |
| SCHEMBL15701128 | 0.81 | FFAR2 (0.47) | FFAR2MEN1KMT2AHDAC1LMNA | |
| SCHEMBL17148297 | 0.79 | S1PR3 (0.45) | FFAR2MEN1KMT2ALMNA | |
| SCHEMBL19446769 | 0.77 | MAP3K5 (0.49) | MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2914592-B1 | INHIBITORS OF CYTOMEGALOVIRUS | BOEHRINGER INGELHEIM INT (DE) | 2017-10-11 | — | — | EP | disclosed |
| US-9334249-B2 | Inhibitors of cytomegalovirus | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-05-10 | — | — | US | disclosed |
| US-20150284348-A1 | INHIBITORS OF CYTOMEGALOVIRUS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-08 | — | — | US | disclosed |
| WO-2014070979-A1 | INHIBITORS OF CYTOMEGALOVIRUS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284348-A1 | INHIBITORS OF CYTOMEGALOVIRUS | CDKN1A, CCNA1, IFNAR1 | FFAR2 4600/4885MEN1 534/4885KMT2A 617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.